New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareProstamax vs Teduglutide

Prostamax vs Teduglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Prostamax
Recovery & Repair
Teduglutide
Summary
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2 hours; once-daily dosing due to gut-specific residence
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.05 mg/kg/day
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
  • Increases intestinal villus height and absorption surface area
  • Reduces intestinal permeability (leaky gut)
  • FDA-approved for short bowel syndrome
  • Reduces parenteral nutrition dependence in SBS patients
  • Promotes intestinal mucosal healing in IBD
  • Increases tight junction proteins ZO-1 and occludin
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
  • Injection site reactions
  • Abdominal pain and bloating
  • Nausea
  • Risk of intestinal polyp growth (requires colonoscopy surveillance)
  • +1 more
Stacks With